These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 14662414)

  • 21. Determinants of response to epidermal growth factor receptor tyrosine kinase inhibition in squamous cell carcinoma of the head and neck.
    Rogers SJ; Box C; Chambers P; Barbachano Y; Nutting CM; Rhŷs-Evans P; Workman P; Harrington KJ; Eccles SA
    J Pathol; 2009 May; 218(1):122-30. PubMed ID: 19197951
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Erlotinib, an effective epidermal growth factor receptor tyrosine kinase inhibitor, induces p27KIP1 up-regulation and nuclear translocation in association with cell growth inhibition and G1/S phase arrest in human non-small-cell lung cancer cell lines.
    Ling YH; Li T; Yuan Z; Haigentz M; Weber TK; Perez-Soler R
    Mol Pharmacol; 2007 Aug; 72(2):248-58. PubMed ID: 17456787
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Basic evidence of molecular targeted therapy for oral cancer and salivary gland cancer.
    Hamakawa H; Nakashiro K; Sumida T; Shintani S; Myers JN; Takes RP; Rinaldo A; Ferlito A
    Head Neck; 2008 Jun; 30(6):800-9. PubMed ID: 18429007
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer.
    Parra HS; Cavina R; Latteri F; Zucali PA; Campagnoli E; Morenghi E; Grimaldi GC; Roncalli M; Santoro A
    Br J Cancer; 2004 Jul; 91(2):208-12. PubMed ID: 15187994
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (Iressa) suppresses proliferation and invasion of human oral squamous carcinoma cells via p53 independent and MMP, uPAR dependent mechanism.
    Lee EJ; Whang JH; Jeon NK; Kim J
    Ann N Y Acad Sci; 2007 Jan; 1095():113-28. PubMed ID: 17404024
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ZD1839 modulates paclitaxel response in renal cancer by blocking paclitaxel-induced activation of the epidermal growth factor receptor-extracellular signal-regulated kinase pathway.
    Sumitomo M; Asano T; Asakuma J; Asano T; Horiguchi A; Hayakawa M
    Clin Cancer Res; 2004 Jan; 10(2):794-801. PubMed ID: 14760103
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model.
    Raben D; Bianco C; Damiano V; Bianco R; Melisi D; Mignogna C; D'Armiento FP; Cionini L; Bianco AR; Tortora G; Ciardiello F; Bunn P
    Mol Cancer Ther; 2004 Aug; 3(8):977-83. PubMed ID: 15299080
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 ('Iressa') is independent of EGFR expression level.
    Campiglio M; Locatelli A; Olgiati C; Normanno N; Somenzi G; Viganò L; Fumagalli M; Ménard S; Gianni L
    J Cell Physiol; 2004 Feb; 198(2):259-68. PubMed ID: 14603528
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PLC and PI3K pathways are important in the inhibition of EGF-induced cell migration by gefitinib ('Iressa', ZD1839).
    Shien T; Doihara H; Hara H; Takahashi H; Yoshitomi S; Taira N; Ishibe Y; Teramoto J; Aoe M; Shimizu N
    Breast Cancer; 2004; 11(4):367-73. PubMed ID: 15604992
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors.
    Lu C; Speers C; Zhang Y; Xu X; Hill J; Steinbis E; Celestino J; Shen Q; Kim H; Hilsenbeck S; Mohsin SK; Wakeling A; Osborne CK; Brown PH
    J Natl Cancer Inst; 2003 Dec; 95(24):1825-33. PubMed ID: 14679152
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (Iressa) suppresses c-Src and Pak1 pathways and invasiveness of human cancer cells.
    Yang Z; Bagheri-Yarmand R; Wang RA; Adam L; Papadimitrakopoulou VV; Clayman GL; El-Naggar A; Lotan R; Barnes CJ; Hong WK; Kumar R
    Clin Cancer Res; 2004 Jan; 10(2):658-67. PubMed ID: 14760089
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined effect of gefitinib ('Iressa', ZD1839) and targeted radiotherapy with 211At-EGF.
    Sundberg AL; Almqvist Y; Orlova A; Blomquist E; Jensen HJ; Gedda L; Tolmachev V; Carlsson J
    Eur J Nucl Med Mol Imaging; 2003 Oct; 30(10):1348-56. PubMed ID: 12937952
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of EGFR-directed therapy in the treatment of breast cancer.
    Morris C
    Breast Cancer Res Treat; 2002 Oct; 75 Suppl 1():S51-5; discussion S57-9. PubMed ID: 12353824
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ("Iressa") and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells.
    Koizumi F; Kanzawa F; Ueda Y; Koh Y; Tsukiyama S; Taguchi F; Tamura T; Saijo N; Nishio K
    Int J Cancer; 2004 Jan; 108(3):464-72. PubMed ID: 14648715
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa).
    Huang SM; Li J; Armstrong EA; Harari PM
    Cancer Res; 2002 Aug; 62(15):4300-6. PubMed ID: 12154033
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reversible G(1) arrest induced by inhibition of the epidermal growth factor receptor tyrosine kinase requires up-regulation of p27(KIP1) independent of MAPK activity.
    Busse D; Doughty RS; Ramsey TT; Russell WE; Price JO; Flanagan WM; Shawver LK; Arteaga CL
    J Biol Chem; 2000 Mar; 275(10):6987-95. PubMed ID: 10702262
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ErbB receptor tyrosine kinases contribute to proliferation of malignant melanoma cells: inhibition by gefitinib (ZD1839).
    Djerf EA; Trinks C; Abdiu A; Thunell LK; Hallbeck AL; Walz TM
    Melanoma Res; 2009 Jun; 19(3):156-66. PubMed ID: 19434003
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gefitinib (Iressa, ZD1839): a novel targeted approach for the treatment of solid tumors.
    Von Pawel J
    Bull Cancer; 2004 May; 91(5):E70-6. PubMed ID: 15582898
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular mechanisms underlying the interaction between ZD1839 ('Iressa') and cisplatin/5-fluorouracil.
    Magné N; Fischel JL; Tiffon C; Formento P; Dubreuil A; Renée N; Formento JL; Francoual M; Ciccolini J; Etienne MC; Milano G
    Br J Cancer; 2003 Aug; 89(3):585-92. PubMed ID: 12888834
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination treatment with ionising radiation and gefitinib ('Iressa', ZD1839), an epidermal growth factor receptor (EGFR) inhibitor, significantly inhibits bladder cancer cell growth in vitro and in vivo.
    Colquhoun AJ; Mchugh LA; Tulchinsky E; Kriajevska M; Mellon JK
    J Radiat Res; 2007 Sep; 48(5):351-60. PubMed ID: 17609586
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.